SAN FRANCISCO, Sept. 7, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP—a national plaintiffs' rights law firm with a premier securities practice group—notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the...
Hence then, the article about hagens berman alerts capricor therapeutics inc nasdaq capr investors to fda review extension for deramiocel amid ongoing securities class action and september 28 lead plaintiff deadline was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Hagens Berman Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to FDA Review Extension for Deramiocel Amid Ongoing Securities Class Action and September 28 Lead Plaintiff Deadline )
Also on site :
- This Airline Just Upgraded Premium Economy With Full Privacy Screens, Electric Recline, and Wireless Charging
- France Launches Global Initiatives to Support Independent Cinema and Establish Framework for Alliance of State Film Commissions: Lumiere Summit
- Nuclear-capable warship that capsized when launched finally joins North Korea’s fleet